Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies

BACKGROUND. Brentuximab vedotin is an antibody-drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule-disrupting agent, to CD30-expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Forero-Torres, Andres, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L., Rosenblatt, Joseph D., Kennedy, Dana A., Younes, Anas
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Lymphoma
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425525/
https://ncbi.nlm.nih.gov/pubmed/22855426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0133
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados